Clinical Trials › NCT07211633
RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsored by TG Therapeutics, Inc.
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 360
Target enrollment
Jul 2025
Start date
Dec 2028
Expected completion
Interventions / Treatments
Ublituximab
Conditions studied
Relapsing Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
